Highlights Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-28 EDT			5-day change	1st Jan Change
11.71 ^USD	-0.51%		-4.49%	-25.32%

09-08	Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon	MT
09-08	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI

Highlights

09-08	Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160	CI
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI
08-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT
05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
04-20	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	CI
03-17	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-17	Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls	MT
03-17	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M	MT
03-16	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	CI
02-24	Monte Rosa Therapeutics, Inc. Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients At Asco Genitourinary Cancers	CI
01-09	Monte Rosa Therapeutics Prices $300 Million Public Offering	MT
01-08	Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share	RE
01-07	Monte Rosa Therapeutics Announces $200 Million Proposed Public Offering	MT
01-07	Monte Rosa Therapeutics announces proposed public offering of common stock and pre-funded warrants	RE
01-07	Monte Rosa Therapeutics, Inc. Announces Positive Interim Phase 1 Data of Mrt-8102 Demonstrating Profound Crp Reductions in Elevated Cvd- Risk Subjects	CI
12-16	Monte Rosa Therapeutics, Inc. Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations	CI
11-08	Monte Rosa Therapeutics, Inc. Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102	CI
11-06	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q3 Revenue $12.8M, vs. FactSet Est of $7.4M	MT
11-06	Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment	RE
25-08-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-07	Monte Rosa Therapeutics Q2 collaboration revenue surges	RE
25-07-21	Monte Rosa Therapeutics, Inc. Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases	CI